Evidence map›Paper›PMID 37591890›Full record

ArticleNature communications2023

C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption.

Abhishek Bharadwaj Sharma, Muhammad Khairul Ramlee, Joel Kosmin, Martin R Higgs, Amy Wolstenholme, George E Ronson, Dylan Jones, Daniel Ebner, Noor Shamkhi, David Sims and 4 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Abhishek Bharadwaj Sharma *Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.ORCID http://orcid.org/0000-0003-2554-1025
Muhammad Khairul Ramlee *Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.
Joel KosminDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.
Martin R HiggsInstitute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK.ORCID http://orcid.org/0000-0002-8218-0089
Amy WolstenholmeDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.
George E RonsonDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.ORCID http://orcid.org/0000-0002-2424-8401
Dylan JonesTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Daniel EbnerTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-6495-7026
Noor ShamkhiDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.
David SimsWeatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Paul W G WijnhovenEarly Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.
Josep V FormentEarly Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.
Ian Gibbs-SeymourDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.ORCID http://orcid.org/0000-0002-6904-2642
Nicholas D LakinDepartment of Biochemistry, University of Oxford, South Parks Road, Oxford, UK. nicholas.lakin@bioch.ox.ac.uk.ORCID http://orcid.org/0000-0003-4999-5814
University of Oxford · GBAstraZeneca (United Kingdom) · GBJohn Radcliffe Hospital · GBUniversity of Birmingham · GB

Funding

Cancer Research UK 24670Medical Research Council MR/P018963/1Medical Research Council MR/P028284/1Medical Research Council MR/V00896X/1Medical Research Council MR/W017350/1
6 · The paper itself

Abstract

While the toxicity of PARP inhibitors to cells with defects in homologous recombination (HR) is well established, other synthetic lethal interactions with PARP1/PARP2 disruption are poorly defined. To inform on these mechanisms we conducted a genome-wide screen for genes that are synthetic lethal with PARP1/2 gene disruption and identified C16orf72/HAPSTR1/TAPR1 as a novel modulator of replication-associated R-loops. C16orf72 is critical to facilitate replication fork restart, suppress DNA damage and maintain genome stability in response to replication stress. Importantly, C16orf72 and PARP1/2 function in parallel pathways to suppress DNA:RNA hybrids that accumulate at stalled replication forks. Mechanistically, this is achieved through an interaction of C16orf72 with BRCA1 and the RNA/DNA helicase Senataxin to facilitate their recruitment to RNA:DNA hybrids and confer resistance to PARP inhibitors. Together, this identifies a C16orf72/Senataxin/BRCA1-dependent pathway to suppress replication-associated R-loop accumulation, maintain genome stability and confer resistance to PARP inhibitors.

Indexed as

BRCA1 ProteinPoly(ADP-ribose) Polymerase InhibitorsR-Loop StructuresDNA DamageDNA HelicasesIntracellular Signaling Peptides and ProteinsRNABRCA1 ProteinDNA HelicasesIntracellular Signaling Peptides and ProteinsPoly(ADP-ribose) Polymerase InhibitorsRNA

Identifiers

PMID37591890
PMCPMC10435583
OpenAlexW4385927801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.